Video webcast now available on-demandBOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: ...

Background: ALB 109564(a) [ALB] is a vinca alkaloid, which functions as a tubulin inhibitor, interfering with microtubule polymerization resulting in metaphase arrest. In preclinical studies, ALB was ...

Tubulin is therefore a relevant target for the discovery of new agents acting as tumor neovasculature disruptors. Researchers from Nanjing Keygen Biotech Co. Ltd. have reported on the design and ...

We recently discovered VERU-111, a new generation of tubulin inhibitor targeting the colchicine binding site, that shows high efficacy against a number of solid tumors. The current study aims to ...

PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors.

In addition, PPARgamma inhibitors do not bind to the standard tubulin-binding site that renders Taxol useless when binding sites change shapes thanks to ongoing genetic mutations.

Tubulin PTMs are critical for the proper functioning of microtubules. Dysregulation of PTMs have been linked to various diseases, including cancer, neurodegeneration, and developmental disorders.